Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer

doi:10.4251/wjgo.v16.i9.3905

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (69)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-6) series.

Item

Count

PDF

HTML

Tables (1-6)

Sum=63

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=3

Sep 15, 2024 (publication date) through Sep 10, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Gastrointest Oncol. Sep 15, 2024; 16(9): 3905-3912
Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.3905

Table 1 Baseline characteristics of the patients (n = 60), n (%)

Characteristics	Value
Median age, years (range)	58 (35-75)
Sex
Male	36 (60)
Female	24 (40)
ECOG performance status
0	42 (70)
1	18 (30)
Metastatic sites
Liver	28 (47)
Peritoneum	24 (40)
Lymph nodes	20 (33)
Lung	12 (20)
Bone	8 (13)
HER2 status
IHC 3+	48 (80)
IHC 2+/FISH+	12 (20)

ECOG: Eastern Cooperative Oncology Group; HER2: Human epidermal growth factor receptor 2; IHC: Immunohistochemistry; FISH: Fluorescence in situ hybridization.

Citation: Zheng CW, Yang YM, Yang H. Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer. World J Gastrointest Oncol 2024; 16(9): 3905-3912
URL: https://www.wjgnet.com/1948-5204/full/v16/i9/3905.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i9.3905